NAD+ Compartmentalization
Why "total cellular NAD+" can be a misleading number
A cell doesn't hold NAD+ in one shared pool. It's divided among at least three subcellular compartments — the nucleus, the cytosol, and the mitochondria — each with its own local concentration, its own supply and consumption, and its own redox state (the balance of NAD+ to NADH, covered in full on NAD+ Redox Biology and the NAD+/NADH Ratio).[1] A measurement of "total cellular NAD+" — the kind most human NMN trials report, typically from whole blood or PBMCs — averages across these compartments and can mask the fact that one compartment rose while another stayed flat or even fell. This is not a hypothetical concern: it's the direct consequence of NAD+ being synthesized separately in different compartments and not moving freely between all of them.
Nucleus, cytosol, and mitochondria: separately supplied
The final step of NAD+ synthesis from NMN — catalyzed by the NMNAT family of enzymes, covered in depth on NMNAT Enzymes Explained — happens in three different locations by three different isoforms: NMNAT1 in the nucleus, NMNAT2 facing the cytosol at the Golgi apparatus, and NMNAT3 inside mitochondria.[2] Because the nuclear envelope contains large pores that allow small molecules like NAD+ to pass relatively freely, the nuclear and cytosolic NAD+ pools are generally treated as functionally connected and are often measured together.[1] The mitochondrial pool is a different story: the inner mitochondrial membrane is a much tighter barrier, and for decades it was genuinely unresolved whether mammalian mitochondria even had a dedicated protein to import NAD+ from the cytosol.
Mitochondrial NAD+ transport: a question that has now been substantially resolved
That specific question is no longer an open mystery the way it was as recently as 2019. In 2020, three independent research groups identified the protein SLC25A51 (also called MCART1) as a mammalian mitochondrial NAD+ transporter.[3][4][5] Across these studies, removing SLC25A51 from cells reduced mitochondrial (but not whole-cell) NAD+ content, impaired mitochondrial respiration and electron transport chain Complex I activity, and directly blocked NAD+ uptake into isolated mitochondria; overexpressing it increased mitochondrial NAD+ uptake.[3][4] This is now established evidence that mammalian cells have a specific, functional mitochondrial NAD+ importer — a genuine resolution of a long-standing question, not a remaining unknown.
What remains genuinely unresolved
Identifying the transporter is not the same as fully characterizing it. Open questions that current evidence has not settled include: the precise transport mechanism and stoichiometry (how SLC25A51 physically moves NAD+ across the membrane); how its activity is physiologically regulated in different tissues and metabolic states; whether its relative importance differs meaningfully across cell types, species, or disease contexts; and how much it, versus mitochondrial NAD+ synthesis by NMNAT3 itself, accounts for the mitochondrial pool under different conditions. This hub does not claim these downstream questions are resolved — only that the core existence question (is there a mammalian mitochondrial NAD+ transporter at all) now has a well-supported answer.
What this means for interpreting NMN research
Because compartments are supplied separately and exchange only partially, a rise in whole-blood or whole-cell NAD+ after oral NMN supplementation does not, by itself, tell you what happened inside the mitochondria, the nucleus, or the cytosol specifically. No human NMN trial reviewed for this hub has directly measured compartment-specific NAD+ concentrations; that data currently comes only from cell and animal studies. Readers should treat "NAD+ rose" and "mitochondrial NAD+ rose" as different claims requiring different evidence, and this hub does not conflate them.
Related reading
For the enzymes that generate NAD+ in each compartment, see NMNAT Enzymes Explained. For how NMN gets into cells in the first place, see NMN Transport and Cellular Uptake. For NAD+'s role in mitochondrial energy production, see NAD+, Mitochondria, and Cellular Energy.
- Total cellular NAD+ measurements average across compartments and can mask compartment-specific changes.
- NMNAT1 (nucleus), NMNAT2 (cytosol/Golgi), and NMNAT3 (mitochondria) supply NAD+ separately.
- Three independent 2020 studies identified SLC25A51 as a mammalian mitochondrial NAD+ transporter.
- This resolves whether mammals have a mitochondrial NAD+ importer at all — regulation and stoichiometry remain open questions.
- No human NMN trial has directly measured compartment-specific NAD+ concentrations.
- Nikiforov A, Kulikova V, Ziegler M. The human NAD metabolome: Functions, metabolism and compartmentalization. Critical Reviews in Biochemistry and Molecular Biology. 2015. PMID: 25837229.
- Berger F, Lau C, Dahlmann M, Ziegler M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. Journal of Biological Chemistry. 2005. PMID: 16118205.
- Luongo TS, Eller JM, Lu MJ, et al. SLC25A51 is a mammalian mitochondrial NAD+ transporter. Nature. 2020. PMID: 32906142.
- Kory N, Uit de Bos J, van der Rijt S, et al. MCART1/SLC25A51 is required for mitochondrial NAD transport. Science Advances. 2020. PMID: 33087354.
- Girardi E, Agrimi G, Goldmann U, et al. Epistasis-driven identification of SLC25A51 as a regulator of human mitochondrial NAD import. Nature Communications. 2020. PMID: 33262325.